First-Line Doxorubicin for Advanced Sarcoma, Not Combo? First-Line Doxorubicin for Advanced Sarcoma, Not Combo?
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
(European Society for Medical Oncology) Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid to be published in The Lancet. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2017 Category: Cancer & Oncology Source Type: news
New data confirms superiority of docetaxel based triplet therapy in gastric cancer
(European Society for Medical Oncology) The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news
Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Tomasz M. Beer, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news
Cabazitaxel Not Superior to Docetaxel in Metastatic CRPC
Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news
A mathematical crystal ball gazes into future of prostate cancer treatment
(University of Colorado Anschutz Medical Campus) Using open data from four previously conducted clinical trials, teams of international researchers designed mathematical models predicting the likelihood that a patient will discontinue docetaxel treatment due to adverse events. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - August 4, 2017 Category: International Medicine & Public Health Source Type: news
Docetaxel-Based Triplet New Standard in Gastric Cancer
Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 21, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Gastrointestinal Cancer News Source Type: news
Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy, according to analyses of two phase III clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Prostate Cancer News Source Type: news
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Randomized, placebo-controlled study confirms ramucirumab, in combination with docetaxel, significantly extended progression-free survival (PFS) in previously treated patients with locally advanced or unresectable or metastatic urothelial carcinoma
INDI... Biopharmaceuticals, Oncology Eli Lilly, CYRAMZA, ramucirumab, urothelial carcinoma, bladder cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 31, 2017 Category: Pharmaceuticals Source Type: news
Adding Selumetinib to Docetaxel Doesn ’ t Up PFS in NSCLC
No improvement in progression - free survival for previously treated advanced KRAS - mutant NSCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 10, 2017 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
MEK Inhibitor Adds No Value in Treatment of KRAS-Mutant NSCLC
Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Lung Cancer News Source Type: news
Blood test may lead to targeted therapy for prostate cancer
Conclusion
Genetic testing is becoming more common in cancer treatment as a way of tailoring treatment to the individual cancer. It's already used in breast cancer, for example. This test could help identify which men that have not responded to hormone treatment are most likely to benefit from two of the newer prostate cancer drugs.
It is good news, because men could then be spared treatment that is unlikely to help them, and directed towards more suitable treatment options. Also, both of these newer drugs are very expensive, so a suitable test could save the NHS a great deal of money.
Meanwhile, those men who are likely t...
Source: NHS News Feed - May 5, 2017 Category: Consumer Health News Tags: Cancer Medication Source Type: news
Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer Vinorelbine, Pertuzumab, and Trastuzumab for Breast Cancer
Is the combination of vinorelbine with dual HER2-targeted therapy a good first-line option for patients needing an alternative to docetaxel?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Metformin Use Does Not Increase Prostate Cancer Survival
Drug given in combination with docetaxel chemotherapy in patients with metastatic disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 11, 2017 Category: Cancer & Oncology Tags: Endocrinology, Oncology, Pharmacy, Urology, Journal, Source Type: news
